Malicon (Citalopram)

Citalopram blocks the serotonin transporter on presynaptic nerve cells, preventing the reabsorption of serotonin back into the neuron. This results in higher concentrations of serotonin in the synaptic cleft, enhancing serotonergic signaling and contributing to mood elevation and anxiety reduction.

The appropriate dose of Malicon is determined by a qualified prescriber based on the individual’s clinical condition, response to therapy, and any relevant medical factors. Patients should follow the dosing instructions provided by their healthcare professional and not adjust the dose on their own.

Citalopram is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no well‑controlled studies in pregnant women. It may be used if the potential benefit justifies the potential risk. Breastfeeding decisions should be made in consultation with a healthcare provider.

To order Malicon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Malicon (citalopram) belongs to the SSRI class, which generally has a favorable side‑effect profile compared with older tricyclic antidepressants and monoamine oxidase inhibitors. Compared with other SSRIs, citalopram is often noted for its relatively low drug‑interaction potential, though dose‑related QT prolongation requires monitoring.

Store Malicon at room temperature, ideally below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use.

Malicon is taken orally, usually once daily with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include the potential for serotonin syndrome when combined with other serotonergic drugs, QT interval prolongation that may lead to cardiac arrhythmias, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy or when dose changes occur.

Malicon should be avoided in patients who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to citalopram or any SSRI component, or have a history of significant QT prolongation. Individuals with uncontrolled severe liver disease should also be evaluated carefully before use.